|
⚲
|
| Keyboard |
| New Leaf Venture Partners LLC
✚
|
|
|---|---|
| CRD # | 163897 |
| SEC # | 801-80793 |
| CIK # | 0001375661, 0001441439, 0001455617, 0001441858, 0001625696, 0001455597, 0001625656, 0001416362, 0001441857, 0001631614 |
| AUM | 408.4 M (2026-03-30) |
| Employees | 4 (50% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 646-871-6420 |
| Address | 156 Fifth Avenue New York, NY 10010 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5 - Fees and Compensation Compensation and Fee Schedules New Leaf typically receives an advisory fee from each of the Funds, which is generally equal to a percentage of the capital commitments to such Fund. The fee percentage and/or the base upon which the fee is calculated may vary with the size of the Fund and may also vary over the life of the Fund, as negotiated and determined at the time the Fund is established and as set forth in its Governing Documents. In addition, a related person of New Leaf, as general partner of a Fund, will typically receive certain allocations and distributions calculated and charged based on a share of capital gains on or capital appreciation of the assets of such Fund, as negotiated and determined at the time such Fund is established and as set forth in its Governing Documents. These allocations and distributions are commonly known as “carried interest.” Different Funds may be subject to different management fees and performance-based compensation arrangements and certain funds (such a co-investment funds) may not be subject to any advisory fees and/or |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Types of Clients New Leaf generally provides investment advice to pooled investment vehicles, such as the Funds. The limited partners of (or investors in) the Funds may include corporations, financial institutions, funds-of-funds, governmental bodies or agencies, insurance companies, endowments, foundations, trusts, estates, high net worth individuals, and pension and profit-sharing plans. In connection with the formation and management of a Fund, New Leaf may form certain related entities for such Fund. New Leaf may establish vehicles to address tax, legal or regulatory issues or requirements of certain investors in such Fund or for other purposes. New Leaf may also form “parallel funds” to invest alongside a Fund in all of its investments. In addition, New Leaf may form “alternative investment vehicles” or special purpose vehicles (collectively, “AIVs”) for the purpose of facilitating certain investments by one or more Funds. Please refer to the Governing Documents of the applicable Fund for more complete details on parallel funds and AIVs. New Leaf may also provide investment management and supervisory services to separate account clients. Minimum Investment Requirements Interests in the Funds are offered in private placements under the U.S. Securities Act of 1933, as amended (the “Securities Act”). As a result, New Leaf generally offers limited partner (or equivalent) interests in the Funds to a limited number of “accredited investors” as defined in Regulation D under the Securities Act and, in most cases, exclusively to “qualified purchasers” as defined in Section 2(a)(51) of the U.S. Investment Company Act of 1940, as amended. In general, the minimum investment commitment required of an investor to participate in a Fund is $5,000,000; however, the general partner of each Fund has discretion to increase or reduce the minimum investment commitment. Investors and prospective investors in each Fund should refer to the Governing Documents of such Fund for more complete information on minimum investment requirements for participation in such Fund. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Edgewise Therapeutics Inc | 16.7 | ||
| Arvinas Inc | 13.5 | ||
| Crinetics Pharmaceuticals Inc | 5.9 | ||
| UNUM Therapeutics Inc | 3.6 | ||
| Rallybio Corp | 1.6 | ||
| Alector Inc | 1.0 | ||
| Passage Bio Inc | 0.7 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | NLV Co-Invest IV LP | [2025-03-31] | 16.7 M | 16.8 M |
| Offered $16,660,000 · Filed 2024-12-31 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | NLV-II SPV-1 LP | [2024-03-28] | 90.8 M | |
| VC | NLV-II SPV-2 LP | [2024-03-28] | 9.0 M | |
| Filed 2023-11-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| VC | NLV Co-Invest III LLC | 2022-03-30 | 9.0 M | |
| VC | NLV Co-Invest II LLC | 2021-03-25 | 5.3 M | |
| VC | New Leaf Biopharma Opportunities II LP | [2019-03-29] | 120.7 M | |
| Offered $200,000,000 · Filed 2018-04-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $200,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | New Leaf Ventures IV LP | [2019-03-29] | 94.4 M | |
| Offered $275,000,000 · Filed 2018-04-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $275,000,000 · Duration One year or less · Finder's Fee $25,000 · Revenue Not Applicable | ||||
| VC | New Leaf Biopharma Opportunities I LP | [2014-12-19] | 10.0 M | |
| Offered $200,000,000 · Filed 2014-12-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $200,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | New Leaf Ventures III LP | [2014-12-19] | 62.4 M | |
| Offered $375,000,000 · Filed 2014-12-03 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $375,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | NLV Partners Co-Invest I LLC | 2014-12-19 | 8.0 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 9 | 408.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 9 | 408.4 |
| By Discretionary | ||
| Discretionary | 9 | 408.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 9 | 408.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 408.4 | |
| Total | 9 | 408.4 |
| Limited Partners | 2011 - 2026 |
|---|---|
| State of Michigan Retirement System |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Vijay Lathi | Executive Officer | 34 | 2 | |
| Jeani Delagardelle | Executive Officer | 32 | 2 | |
| Liam Ratcliffe | Executive Officer | 25 | 2 | |
| Ronald Hunt | Executive Officer | 25 | 2 | |
| Ron Hunt | Executive Officer | 19 | 2 | |
| Philippe Chambon | Executive Officer | 13 | 2 | |
| Isaac Manke | Executive Officer | 8 | 2 | |
| Nlv SPV GP LLC | Executive Officer | 3 | 2 | |
| New Leaf Venture Management III LLC | Director | 3 | 2 | |
| Craig Slutzkin | Executive Officer | 3 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001375661] | |
| 4 | [0001375661] | |
| SC 13G | [0001375661] | |
| 3 | [0001441439] | |
| 4 | [0001441439] | |
| SC 13D | [0001441439] | |
| SC 13G | [0001441439] | |
| 3 | [0001441857] | |
| 4 | [0001441857] | |
| 3 | [0001441858] | |
| 4 | [0001441858] | |
| 3 | [0001455597] | |
| 4 | [0001455597] | |
| 3 | [0001455617] | |
| 4 | [0001455617] | |
| 3 | [0001625656] | |
| 4 | [0001625656] | |
| 3 | [0001625696] | |
| 4 | [0001625696] | |
| D | [0001625696] | |
| SC 13G | [0001625696] | |
| 13F-HR | [0001631614] | |
| 3 | [0001631614] | |
| 4 | [0001631614] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
|
2024-03-11 | Disposed to issuer | 299,430 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2024-03-11 | Disposed to issuer | 1,463,386 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
|
2024-03-11 | Disposed to issuer | 686,000 | ||
|
Harpoon Therapeutics Inc HARP
8.000% Series A Redeemable Preferred Stock
|
2024-03-11 | Disposed to issuer | 10,000 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
|
2024-03-11 | Disposed to issuer | 85,750 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2024-03-11 | Disposed to issuer | 395,783 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
|
2023-10-25 | Buy | 686,000 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2023-10-25 | Buy | 1,372,000 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2023-10-25 | Buy | 171,500 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
|
2023-10-25 | Buy | 85,750 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2021-01-11 | Buy | 235,294 | $17.00 | 3,999,998 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-16 | Sell | 26,108 | $37.01 | 966,257 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-16 | Sell | 69,292 | $36.54 | 2,531,930 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-16 | Sell | 28,626 | $37.01 | 1,059,448 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-16 | Sell | 75,974 | $36.54 | 2,776,090 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-15 | Sell | 71,550 | $36.09 | 2,582,240 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-15 | Sell | 78,450 | $36.09 | 2,831,261 |
|
Principia Biopharma Inc PRNB
Common Stock
|
2019-08-13 | Sell | 49,991 | $35.00 | 1,749,685 |
|
Principia Biopharma Inc PRNB
Common Stock
|
2019-08-13 | Sell | 250,009 | $35.00 | 8,750,315 |
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2019-02-12 | Buy | 214,285 | $14.00 | 2,999,990 |
| showing 20 of 131 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Auldbrass Partners LP
✚
|
NY | 412.9 M |
|
Auxo Investment Partners LLC
✚
|
MI | 412.0 M |
|
Vortus Investment Advisors LLC
✚
|
TX | 411.7 M |
|
Peloton Equity LLC
✚
|
CT | 409.5 M |
|
Greenridge Equity Partners LLC
✚
|
TX | 408.8 M |
|
Bridge Growth Partners LLC
✚
|
NY | 407.0 M |
|
Generation Partners Management LLC
✚
|
401.6 M | |
|
ROG IX LLC
✚
|
TX | 401.0 M |
|
Palm Peak Capital LLC
✚
|
FL | 400.8 M |
|
ValueQuest Advisers LLC
✚
|
NY | 400.8 M |